Suppr超能文献

系统性免疫炎症指数预测下肢动脉硬化闭塞症介入治疗后的再狭窄。

Systemic Immune-Inflammation Index Predicts Restenosis after Interventions for Lower Extremity Arteriosclerosis Obliterans.

机构信息

Department of Intervention, Harrison International Peace Hospital, 053000 Hengshui, Hebei, China.

出版信息

Heart Surg Forum. 2023 May 31;26(3):E225-E233. doi: 10.1532/hsf.5303.

Abstract

BACKGROUND

To investigate the association between the pretreatment systemic immune-inflammation index (SII) and restenosis after interventions for lower extremity arteriosclerosis obliterans (ASO).

METHODS

We retrospectively evaluated 309 patients with ASO who underwent endovascular interventions between January 2018 and December 2021. Pretreatment inflammatory markers, including the SII, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic inflammation response index (SIRI), aggregate index of systemic inflammation (AISI), and C-reactive protein (CRP) were collected. The logistic regression model was used to determine the associations between these inflammatory markers and restenosis. Clinical manifestations, ankle-brachial index (ABI), and quality of life after intervention also were compared.

RESULTS

The pretreatment SII (p < 0.001), NLR (p < 0.001), PLR (p < 0.001), SIRI (p = 0.002), AISI (p < 0.001), and CRP (p = 0.036) were significantly higher in patients with restenosis than in those without restenosis. Among the four markers, SII had the highest area under the curve (AUC) in predicting restenosis (SII vs. NLR vs. PLR vs. SIRI vs. AISI vs. CRP: 0.715 vs. 0.689 vs. 0.695 vs. 0.643 vs. 0.691 vs. 0.596). Multivariate analysis revealed that the pretreatment SII was the only independent factor for restenosis (hazard ratio [HR]: 4.102; 95% confidence interval [CI]: 1.155-14.567; p = 0.029). Moreover, a lower SII was associated with significantly better improvements in clinical manifestations (Rutherford classification 1-2: 67.5% vs. 52.9%, p = 0.038) and ABI (median: 0.29 vs. 0.22; p = 0.029), together with better quality of life (p < 0.05 for physical functioning, social functioning, pain, and mental health).

CONCLUSIONS

The pretreatment SII is an independent predictor of restenosis after interventions in patients with lower extremity ASO, providing more accurate prognosis prediction than other inflammatory markers.

摘要

背景

本研究旨在探讨下肢动脉硬化闭塞症(ASO)患者经介入治疗后,治疗前的全身免疫炎症指数(SII)与再狭窄之间的关系。

方法

回顾性分析了 2018 年 1 月至 2021 年 12 月期间接受腔内介入治疗的 309 例 ASO 患者的资料。收集患者治疗前的炎症标志物,包括 SII、中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)、全身炎症反应指数(SIRI)、全身炎症综合指数(AISI)和 C 反应蛋白(CRP)。采用 logistic 回归模型分析这些炎症标志物与再狭窄之间的关系。比较两组患者的临床表现、踝肱指数(ABI)和介入治疗后的生活质量。

结果

与无再狭窄组相比,再狭窄组患者的治疗前 SII(p < 0.001)、NLR(p < 0.001)、PLR(p < 0.001)、SIRI(p = 0.002)、AISI(p < 0.001)和 CRP(p = 0.036)均显著升高。在这四个标志物中,SII 对再狭窄的预测价值最高(AUC:SII 与 NLR 与 PLR 与 SIRI 与 AISI 与 CRP:0.715 与 0.689 与 0.695 与 0.643 与 0.691 与 0.596)。多因素分析显示,治疗前 SII 是再狭窄的唯一独立预测因素(HR:4.102;95%CI:1.155-14.567;p = 0.029)。此外,较低的 SII 与临床表现(Rutherford 分级 1-2:67.5%与 52.9%,p = 0.038)和 ABI(中位数:0.29 与 0.22;p = 0.029)的显著改善以及更好的生活质量相关(躯体功能、社会功能、疼痛和心理健康评分均<0.05)。

结论

治疗前 SII 是下肢 ASO 患者经介入治疗后再狭窄的独立预测因素,其预测价值优于其他炎症标志物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验